Fenaris does not merely prepare documentation; we actively design, align, and optimize Quality Management Systems so that they are audit-ready, scalable, and defensible throughout the entire device lifecycle. This includes harmonized integration of risk management, clinical evaluation, post-market surveillance, and vigilance processes as required under MDR Annexes II, III, and IX.

A key strength of Fenaris lies in our specialization in supporting Asian medical device manufacturers entering the European market. We understand the structural and regulatory challenges that often arise when Asian clinical data, performance studies, or post-market evidence are reviewed under EU MDR scrutiny. Differences in study design, endpoints, documentation standards, and clinical practice frequently require targeted regulatory translation rather than simple submission. Our team and regional partners focus specifically on bridging these gaps, restructuring clinical evidence strategies, and proactively addressing Notified Body concerns before they become formal nonconformities.

By combining regulatory strategy, Quality Management System implementation, clinical evidence alignment, and direct coordination with our Notified Body partner, Fenaris delivers a streamlined MDR CE certification process that minimizes delays, reduces regulatory risk, and accelerates EU market entry without compromising compliance or scientific credibility.

Contact Fenaris to evaluate your MDR CE timeline and certification strategy free of charge.
Engage with us to achieve fast, reliable, and cost-effective EU MDR certification.